Nile Therapeutics, Inc. Stock Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 21.4M | Sales 2025 * | 89.52M | Capitalization | 170M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 8M | EV / Sales 2024 * | 7.96 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-5.61
x | P/E ratio 2025 * |
55.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.66% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.73% | 22.15B | |
-17.37% | 21.02B | |
-8.45% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |